In next-generation antibody discovery and engineering, precision is everything. Even the smallest oversight can cascade through the workflow propagating errors, compromising data integrity, and ultimately affecting critical decisions.

This webinar brings together experts from Dotmatics, BioGlyph, and leading industry scientists to explore how achieving fidelity of precision from sequence design to data integration can transform antibody R&D outcomes. We’ll examine how modern platforms like Luma and BioGlyph are solving long-standing challenges in data fidelity, workflow integration, and early error detection, enabling scientists to make the best possible decisions at every stage.

Through real-world commentary from experienced researchers, we’ll highlight the practical impacts of avoiding error propagation, the value of unified data environments, and the game-changing potential of integrated discovery-to-design platforms.

Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.